Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]
Marketing Status approved
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
NDC Product Code 70010-741; 62207-742; 70010-742; 70010-743
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrial fibrillation02.03.03.0020.000103%
Atrioventricular block02.03.01.0020.000010%-
Atrioventricular block first degree02.03.01.0040.000010%
Atrioventricular block second degree02.03.01.005--
Back pain15.03.04.005--
Blindness transient06.02.10.006;
Blood creatinine increased13.13.01.004--
Blood pressure fluctuation24.06.01.0020.000099%-
Blood urea increased13.13.01.006---
Blood uric acid increased13.02.04.001---
Body temperature increased13.15.01.001---
Burning sensation17.02.06.001;
Cardiac failure02.05.01.0010.000071%
Cardiac failure congestive02.05.01.0020.000084%-
Cardiac tamponade02.06.01.0010.000010%
Cerebral ischaemia24.04.06.003;
Cerebrovascular disorder24.03.05.002;
Chest discomfort22.12.02.002;;
Chest pain22.12.02.003;;
Chronic lymphocytic leukaemia16.01.06.001;
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 16 Pages
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene